BL-B01D1 targets EGFR/HER3 on tumor cells, is internalized, and releases a camptothecin-class topoisomerase I inhibitor (brengitecan) that causes DNA damage; topoisomerase I is the intracellular enzymatic target of the payload, not the antigen used for cell targeting.